Tegafur (INN) is a chemotherapeutic 5-FU prodrug used in the treatment of cancers. It is a component of tegafur-uracil. When metabolized, it becomes 5-FU. T egafur-uracil is a formulated therapeutic oral agent consisting of a combination of the 5-fluorouracil (5-FU) congener prodrug tegafur (tetrahydrofuranyl-5-fluorouracil) and uracil (1:4). The high concentration of uracil reversibly inhibits the uracil-reducing enzyme dihydropyrimidine dehydrogenase (DPD), thereby inhibiting first-pass DPD-mediated hepatic metabolism of the uracil analogue 5-FU and permitting administration of 5-FU as the orally bioavailable prodrug tegafur. Tegafur is bioactivated to 5-FU by liver microsomal cytochrome P450 enzymes.
Appearance & Physical State: White Crystalline Powder
Density: 1.45 g/cm3
Melting Point: 168-171ºC
Refractive Index: 1.557
Stability: Stable under normal temperatures and pressures.
Vidarabine; Flupirtine maleate; Halofuginone hydrobromide; Rifampicin; Rifaximin; Rifapentine; Streptozocin